Modality
Multispecific
MOA
JAK1i
Target
PD-1
Pathway
Cell Cycle
RCC
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Dec 2025
Phase 1Current
NCT05071466
1,697 pts·RCC
2018-03→2025-12·Not yet recruiting
1,697 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-233mo agoPh2 Data· RCC
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2025-12-23 · 3mo ago
RCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05071466 | Phase 1/2 | RCC | Not yet recr... | 1697 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Motanaritide | Intellia | Approved | PD-1 | |
| 450-8514 | Astellas | Phase 3 | RET |